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Background: Although major improvements are achieved after cure of Cushing syndrome (CS), 
fatigue and decreased quality of life persist. This is the first study to measure aerobic exercise 
capacity in patients in remission of CS for more than 4 years in comparison with matched 
controls, and to investigate whether the reduction in exercise capacity is related to alterations 
in muscle tissue.
Methods: Seventeen patients were included. A control individual, matched for sex, estrogen 
status, age, body mass index, smoking, ethnicity, and physical activity level was recruited for 
each patient. Maximal aerobic capacity (VO2peak) was assessed during incremental bicycle 
exercise to exhaustion. In 8 individually matched patients and controls, a percutaneous 
muscle biopsy was obtained and measures were made of cross-sectional areas, capillarization, 
and oxphos complex IV (COXIV) protein content as an indicator of mitochondrial content. 
Furthermore, protein content of endothelial nitric oxide synthase (eNOS) and eNOS 
phosphorylated on serine1177 and of the NAD(P)H-oxidase subunits NOX2, p47phox, and p67phox 
were measured in the microvascular endothelial layer.
Findings: Patients showed a lower mean VO2peak (SD) (28.0 [7.0] vs 34.8 [7.9] ml O2/kg bw/
min, P < .01), maximal workload (SD) (176 [49] vs 212 [67] watt, P = .01), and oxygen pulse (SD) 
(12.0 [3.7] vs 14.8 [4.2] ml/beat, P < .01) at VO2peak. No differences were seen in muscle fiber 
type–specific cross-sectional area, capillarization measures, mitochondrial content, and protein 
content of eNOS, eNOS-P-ser1177, NOX2, p47phox, and p67phox.
Copyedited by: Oup
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/4/dgz286/5681573 by guest on 17 M
arch 2020
Interpretation: Because differences in muscle fiber and microvascular outcome measures are 
not statistically significant, we hypothesize that cardiac dysfunction, seen in active CS, persists 
during remission and limits blood supply to muscles. (J Clin Endocrinol Metab 105: 1–11, 2020)
Key Words:  Cushing syndrome, long-term remission, VO2peak, muscle capillarization, muscle 
mitochondrial content
Cushing syndrome (CS), in most cases, is of pituitary or adrenal origin. Skilled surgeons supported by ex-
pert endocrinologists have high success rates in reducing 
plasma cortisol levels to the normal range and achieving 
substantial improvements in phenotype in patients. 
However, after remission most patients, independent of 
the origin of CS, report subjective feelings of fatigue and 
limitations in their ability to perform exercise (1-3).
The present study aimed to be the first to measure aer-
obic exercise capacity during incremental cycling exer-
cise to exhaustion in patients in remission of CS for 4 
to 28 years. The second aim was to investigate whether 
the patients for a given habitual physical activity level 
(including exercise activities) have a lower maximal 
aerobic capacity (VO2peak) than healthy matched con-
trols. The third aim was to investigate whether the 
mechanisms limiting VO2peak in patients reside at the 
level of the vastus lateralis muscle taken as represen-
tative of the major muscles used during walking, run-
ning, and cycling exercise. The major determinants of 
VO2peak during incremental exercise at the level of the 
contracting muscles are mitochondrial content, capil-
lary density, and the vasodilatory response of terminal 
arterioles (TAs).
In this study we measured VO2peak in patients in 
long-term remission of CS using the gold-standard 
method measuring VO2 during a stepwise incremental 
exercise test until exhaustion. A comparison was made 
with a control group individually matched for age, sex, 
body mass index (BMI), smoking, physical activity level, 
and ethnicity. These conditions and characteristics were 
selected because they are known to affect VO2peak inde-
pendently of previous CS. Therefore, this design, with 
all other conditions being equal, allowed us to investi-
gate whether previous CS is an independent condition 
reducing VO2peak and not just the result of, for example, 
a lower physical activity level or a higher BMI.
To investigate the potential mechanism(s) that led 
to a reduction in VO2peak in patients compared to their 
controls, we measured in percutaneous muscle biopsies 
1) mitochondrial content, 2) several measures of capil-
lary density and structure, and 3)  the cross-sectional 
area (CSA) of type 1 and type 2 fibers as measures of 
potential muscle fiber atrophy.
Previous reviews of research (4, 5) have shown that intra-
abdominal (visceral) obesity and hypertriglyceridemia in 
sedentary obese individuals leads to impairment in the 
exercise-induced vasodilation of TAs in the muscles. This 
then leads to a reduction in the exercise-induced recruit-
ment of additional capillaries and capillary surface area 
and, consequently, to a reduction in the transendothelial 
transport rate of oxygen and nutrients/fuels from the 
blood in the capillary lumen into the contracting muscle fi-
bers. Previous research (6) suggests that in sedentary obese 
young men with metabolic syndrome, an imbalance exists 
between the protein content of endothelial nitric oxide 
synthase (eNOS) and the NAD(P)H-oxidase complex. 
A reduction in protein content and serine1177 phosphor-
ylation of eNOS reduces eNOS activity and the produc-
tion of the vasodilator NO, whereas increased expression 
of subunits of the NAD(P)H-oxidase protein complex 
(NOX2, p47phox, and p67phox) increases the production 
of superoxide anions and subsequent quenching of NO. 
These measurements were made in the present study to 
test the hypothesis that the eNOS/NAD(P)H-oxidase 
protein ratio is lower in patients than in matched controls 
and therefore may limit exercise-induced vasodilation 
of TAs and recruitment of additional capillaries during 
exercise.
Participants and Methods
Participants
In this cross-sectional, matched, case-control study, pa-
tients who were successfully treated for CS between 1985 
and 2009 in the Radboud University Nijmegen Medical 
Center and Leiden University Medical Center, both in the 
Netherlands, could be included. Medical records of all 
patients were reviewed to assess data on demographics, 
diagnosis of CS, etiology of CS, type and number of treat-
ments received, duration of postoperative glucocorticoid 
treatment, and follow-up data on remission, recurrences, 
and hormonal deficiencies. Adult patients (age > 18 years) 
in long-term (> 4 years) remission from CS were eligible 
for this study. Remission was defined as suppression of 
plasma cortisol to 50  nmol/L or less after 1  mg dexa-
methasone overnight and absence of clinical signs and 
symptoms of active hypercortisolism, documented no 
longer than 1 year before inclusion (7). Individuals with 
hormonal deficiencies, except for adequately treated 
hypothyroidism (free T4 range 8.0-22.0 pmol/L), were 
excluded from this study. All eligible pituitary CS patients 
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had been tested after their last pituitary surgery for 
growth hormone (GH) deficiency by means of an insulin 
tolerance test, because GH deficiency is known to have 
a strong influence on VO2 peak (8). GH deficiency was 
defined as a maximal GH response less than 15.3 mU/L 
during an insulin tolerance test (9). Serious comorbidity 
(ie, active malignancy, serious psychiatric pathology, and 
known diabetes mellitus), pregnancy, use of medication 
interfering with the cardiovascular system (angiotensin-
converting enzyme inhibitors, calcium antagonists, 
angiotensin II receptor antagonists, beta-blockers), severe 
cardiopulmonary disease, and orthopedic and/or neuro-
logical diseases were exclusion criteria.
For each patient, a control matched for sex, age, BMI, 
smoking (yes/no), ethnicity, and physical activity level 
was recruited from the general population by means of 
an advertisement in a newspaper. Female patients were 
matched for estrogen status and oral contraceptive use.
Physical activity was estimated before exercise testing 
using metabolic equivalent of task scores (METS). 
Participants reported their weekly physical activities, 
enabling the estimation of their daily average METS 
score using the 2011 Compendium of Physical Activities 
(10). Daily energy expenditure (EE) was assessed 
using an activity monitor (Sensewear Pro3 Armband, 
SWA, Body Media) after inclusion to ensure adequate 
matching on physical activity level.
This study was approved by the institutional medical 
ethics committees and conformed to the Declaration of 
Helsinki. All participants provided written informed 
consent.
Methods
Aerobic exercise capacity
Aerobic exercise capacity was assessed using an exercise 
stress test on a stationary bicycle ergometer (Lode, Excalibur 
Sport) using a progressive, incremental exercise protocol. 
All participants refrained from alcohol, caffeine, and inten-
sive physical exercise for at least 24 hours before testing. 
All tests were performed in laboratory conditions with con-
sistent temperature (18°C-20°C) and humidity (35%). All tests 
started at the same time of day (9:00 am). Participants were 
instructed to cycle at 60 to 80 rotations per minute to vol-
itional fatigue or until they reached symptom-limited exhaus-
tion. Spiroergometric equipment (Oxycon Alpha, Jaeger) was 
used to continuously measure breath-by-breath minute venti-
lation (VE), respiratory rate, oxygen consumption (VO2), and 
carbon dioxide production (VCO2), with calculations of the re-
spiratory exchange ratios (RER, VCO2/VO2). Aerobic exercise 
capacity was determined as the peak oxygen uptake in milli-
liters O2/min/kg (VO2peak). Oxygen pulse, a noninvasive esti-
mate of cardiac stroke volume, was calculated as the ratio of 
peak VO2 (mL/min) to peak heart rate (beats per minute) (11). 
Values were obtained from expired air as 30-second averages. 
A 12-lead electrocardiogram was used to observe heart rate. 
Blood pressure was measured manually before testing to en-
sure volunteer safety. Capillary blood lactate (Accutrend Plus, 
Roche) was measured before and 2 minutes after the test. On 
cessation of exercise, participants reported their rating of per-
ceived exertion using a 0 to 10 Borg scale (12). VO2peak was 
deemed to have been reached and the test data were included 
in the analysis when 3 of the following 4 criteria were met: 
1) clinical signs of full exhaustion including Borg scale score of 
8 or greater, 2) RER of 1.10 or greater at cessation, 3) maximal 
heart rate within 10  beats of the maximum predicted heart 
rate (220  – age), and 4)  flattening of the VO2 uptake curve 
(≤ 150 mL increase during the last minute of exercise) (13).
Physical activity levels
Average daily EE (mean total calories used per day), 
average active EE (mean total calories used during activities 
>  3 METS), average daily sedentary hours (activity  <  1.5 
METS), and average daily active hours (activity > 3 METS) 
were assessed using an activity monitor (Sensewear Pro3) 
around the upper right arm. The activity monitor measured 
physical activity 24 hours per day for 7 consecutive days close 
to the exercise stress test. Each 24-hour interval was analyzed 
from 12:00 pm to 12:00 pm the following day and was in-
cluded when the monitor recorded at least 90% of the time in 
each 24-hour cycle. The activity monitor has been validated to 
examine EE and activity behavior in humans (14).
Muscle biopsy
A muscle biopsy was taken from the vastus lateralis muscle 
using the percutaneous needle biopsy technique under local 
anesthesia (1% lidocaine) as previously described (15). The 
vastus lateralis muscle was chosen because it is easy to access by 
percutaneous biopsy and the fact that this muscle makes a sig-
nificant contribution to the workload of the upper leg muscles 
during exercise, especially during cycling. Furthermore, this is 
the muscle that has previously been investigated in active CS 
(16). Samples were embedded in Tissue-Tek OCT Compound 
(Sakura Finetek Europe) and frozen in liquid nitrogen–cooled 
isopentane (Sigma-Aldrich). Samples were stored at –80°C.
Skeletal muscle mitochondrial content and 
capillarization
The method to make a fiber type–specific quantitative esti-
mate of mitochondrial content from the fluorescence intensity 
of oxphos complex IV (COXIV) has been described previously 
(17). Briefly, muscle sections were first incubated with primary 
antibodies targeting COXIV (Invitrogen) and myosin heavy 
chain type  I (A4.840-c, DSHB, developed by Dr Blau), fol-
lowed by incubation with appropriate secondary antibodies 
(Alexa Fluor goat antimouse immunoglobulin  G2a 488 and 
Alexa Fluor goat antimouse immunoglobulin M 546, respect-
ively) and a wheat germ agglutinin (WGA) Alexa Fluor 350 
conjugate (to visualize the cell border) (Invitrogen).
The method to assess fiber type–specific capillarization 
has been described previously (6). Muscle cross-sections 
were first incubated with the same myosin heavy chain type 
I  primary antibody to identify the type I  fibers. This was 
followed by incubation with a goat antimouse immuno-
globulin  M 546 secondary antibody in combination with 
Ulex Europaeus-fluorescein isothiocyanate (FITC) conjugate 
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(UEA-I-FITC; Sigma-Aldrich) and the WGA-350 conjugate. 
A Leica DMI600B microscope with a 40×/0.6 NA objective, 
coupled to a Leica DFC365 FX CCD microscope camera 
(Leica Microsystems), was used to obtain digital images of 
cross-sectionally orientated muscle. DAPI (4′,6-diamidino-2-
phenylindole) UV (340-380 nm) and FITC (465-495 nm) ex-
citation filters both were used to view the Alexa Fluor 350 and 
488 fluorophores, respectively, and a Texas red (540-580 nm) 
excitation filter was used to view sections stained with Alexa 
Fluor 546. Image processing and analysis was undertaken 
using Image Pro Plus 5.1 software (Media Cybernetics Inc). 
A total of 50 ± 11 fibers per muscle cross-section were ana-
lyzed. Fluorescence staining intensity was used to indicate 
differences between patients and their matched controls in 
mitochondrial content of each fiber type. Capillaries were also 
quantified in a fiber type–specific manner manually, using the 
UEA-I, WGA-350, and myosin heavy chain images (6). The 
following indexes of muscle tissue fibers and capillarization 
were measured: 1) total fiber cross-sectional area of type I and 
type II fibers, 2) number of capillaries around a fiber (capillary 
contacts), 3) capillary density, and 4) capillary-fiber perimeter 
exchange index.
Quantitative immunofluorescence microscopy was used 
to estimate skeletal muscle eNOS, eNOS-P- ser1177, NOX2, 
p47phox, and p67phox protein content.
Endothelial-specific eNOS content and eNOS ser1177 
phosphorylation were assessed using previously estab-
lished methods (18, 19), with the modification that the 
method was adapted so the eNOS-P-ser1177/eNOS ratio 
was calculated for individual vessels. Methods to assess 
endothelial-specific and membrane-specific NOX2 content 
have also been described previously (18, 19). Assessment of 
endothelial-specific p47phox and p67phox apart from using 
different primary antibodies uses the same method as de-
scribed for NOX2.
Sections were fixed in acetone and ethanol (3:1). For assess-
ment of eNOS ser1177/eNOS ratio, sections were triple-stained 
with antibodies against eNOS (Transduction Laboratories) 
and p-eNOS ser1177 (Cell Signaling Technology). For assess-
ment of NOX2 p47phox and p67phox content, sections were 
double-stained with antibodies against NOX2, p47phox, or 
p67phox (all kind gifts from Prof Mark Quinn, Montana State 
University). All sections were then incubated with appropriate 
secondary antibodies (Invitrogen) in combination with the 
endothelial marker UEA-I-FITC (Sigma-Aldrich). A  plasma 
membrane marker, WGA-633 (Invitrogen), was also included 
when staining samples for NOX2.
Images were acquired using an inverted confocal micro-
scope (Zeiss LSM-710, Carl Zeiss) with a 40× NA oil im-
mersion objective. Alexa Fluor 405 was excited using the 
405-nm line of the diode laser and detected with 371 to 
422 nm emission. FITC fluorescence was excited with a 488-
nm line of the argon laser and detected with 493 to 559 nm 
emission. Alexa Fluor 546 and 633  fluorophores were ex-
cited with 543-nm and 633-nm lines of the helium-neon 
laser and 548 to 623 nm and 638 to 747 nm emission, re-
spectively. Identical settings were used for all image captures 
within each participant.
All image analysis was performed using ImagePro Plus 
5.1 (Media Cybernetics Inc). The endothelial (UEA-I-FITC) 
outline was overlaid onto the corresponding vascular en-
zyme image. Fluorescence intensity of the vascular enzyme 
signal was then quantified within the endothelial-specific 
area. Because eNOS and eNOS ser1177 phosphorylation had 
been stained on the same sections, it was possible to establish 
each eNOS ser1177/eNOS ratio on an individual-vessel basis 
because the same endothelial outline could be placed over 
both eNOS and eNOS ser1177 images. Cell membrane–spe-
cific fluorescence for NOX2 was determined using the WGA-
633 stain to create an outline of the cell membrane. This 
mask was then overlaid onto the corresponding image to de-
termine membrane–specific fluorescence intensity for NOX2.
Statistical analysis
Statistical analysis was performed using SPSS (version 22.0). 
Data are expressed as mean and SDs unless stated otherwise. 
Before analysis, data were checked for normality of distribution 
using the Shapiro-Wilk test. Differences between the groups 
were analyzed using paired t  tests after confirmation of ad-
equate group matching using independent t tests. Correlations 
between aerobic exercise capacity and clinical parameters were 
determined using the Spearman correlation coefficient. The 
level for significance was set at α equal to .05 or less.
Results
Baseline characteristics
Seventeen patients in long-term remission from CS, 
and 17 healthy controls matched for sex, age, BMI, 
estrogen status, ethnicity, physical activity level, and 
smoking habits, were included (Table 1). Ten (58.8%) 
patients had CS of pituitary origin and were treated 
by selective transsphenoidal pituitary adenomectomy. 
Seven (41.2%) patients had CS of adrenal origin and 
were treated by unilateral adrenalectomy.
Aerobic exercise capacity
The mean VO2peak of patients in long-term remission 
from CS was significantly lower compared to matched 
controls (P < .01) (Fig. 1). A significantly lower maximal 
workload (P = .01) and shorter test duration (P = .02) 
was observed in patients in long-term remission from 
CS compared to the control group. VE was signifi-
cantly lower in patients in long-term remission from CS 
(P = .02). This lower VE consisted of a lower respiratory 
rate (P  =  .047) with comparable tidal volumes in the 
patients and their controls. Furthermore, oxygen pulse 
was lower in the patients compared to their controls 
(P = .01). The peak heart rate, RER, and posttest blood 
lactate concentrations were not statistically different 
between the groups (Table 2) but occurred at a lower 
absolute workload (P = .01) in the former CS patients.
Physical activity levels
No differences were found in the current average 
daily total EE, active EE, total daily sedentary time, and 
total daily active time (Table 2).
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Correlations between aerobic exercise capacity 
and clinical characteristics
In the patient group, older age (r = –0.62, P <  .01) 
was significantly associated with a lower VO2peak. 
Adequately treated hypothyroidism in patients was also 
associated with a lower VO2peak (r  =  –0.65, P  <  .01). 
CS subtype, BMI, smoking, age at diagnosis, estrogen 
status, and duration of remission were not significantly 
correlated with VO2peak. In the control group, older age 
(r  =  –0.55, P  =  .02) was significantly associated with 
a lower VO2peak. After exclusion of the 4 patients with 
treated hypothyroidism and their controls, VO2peak re-
mained significantly lower in patients (25.2  ±  3.8) vs 
controls (32.5 ± 5.5) (P < .01)) (Table 3).
Skeletal muscle capillarization and mitochondrial 
content
Thirteen matched pairs provided informed consent 
to undergo skeletal muscle biopsy. Owing to technical 
problems (frost damage) and/or a small biopsy sample 
size in 1 of the 2 members of a matched pair, mitochon-
drial content and skeletal muscle capillarization could 
not be determined in 5 matched pairs. No differences 
were found between the patients and their matched 
controls with regard to muscle total fiber CSA, capillary 
contacts, capillary density, and capillary-fiber perimeter 
exchange index. In addition, no differences were found 
between patients and controls in mitochondrial content 
(Table 4). The range for the mitochondrial contents and 
each of the capillary measures was large in both groups, 
but the mean patient/control ratio for each of these 
measures in the individually matched pairs was close to 
1 (Tables 3 and 4).
Skeletal muscle eNOS, eNOS-P-ser1177, NOX2, 
p47phox, and p67phox protein content
In 8 matched pairs skeletal muscle eNOS and eNOS-
P-ser1177 protein content and eNOS ser1177 phosphoryl-
ation (Fig. 2), and in 7 matched pairs NOX2, p47phox, 
and p67phox protein content were determined specifically 
in the endothelial layer of muscle capillaries and terminal 
arterioles (Fig. 3). NOX2 was also quantified on the same 
slides in the plasma layer of the skeletal muscle fibers. 
No statistically significant differences were detected in 
the mean protein content of eNOS, eNOS-P-ser1177, and 
Table 1. Characteristics of patients and controls
Patients (n = 17) Controls (n = 17) P
Sex: female/male, no. 15/2 15/2 1.00
Age at time of test, y 45.7 ± 11.1 45.2 ± 10.1 .89
Age at diagnosis, y 34.0 ± 10.2 – –
Duration of remission: median (range), y 11.3 (4–28) – –
Height, cm 171.6 ± 6.3 174.1 ± 6.3 .25
Weight, kg 73.9 ± 8.1 76.1 ± 9.8 .50
BMI, kg/m2 25.1 ± 2.4 25.1 ± 2.6 .95
Systolic BP, mm Hg 126 ± 13 130 ± 12 .32
Diastolic BP, mm Hg 81 ± 7 82 ± 2 .70
Cushing syndrome type, No. (%)  – –
Pituitary 10 (58.8)   
Adrenal 7 (41.2)   
Duration of postoperative glucocorticoid treatment, d  – –
Pituitary 371 (203)   
Adrenal 397 (298)   
Treated hypothyroidism, No. (%) 4 (23.5) – –
Estrogen status in women, No. (%)    
Sufficient (premenopausal) 10 (66.7) 10 (66.7) 1.00
Insufficient (postmenopausal) 5 (33.3) 5 (33.3)  
Smoking, No. (%)    
Yes 1 (5.9) 1 (5.9) 1.00
No 16 (94.1) 16 (94.1)  
Data are presented as means ± SD unless stated otherwise.
Abbreviations: BMI, body mass index; BP, blood pressure.
Figure 1. VO2peak of patients in long-term remission of Cushing 
syndrome compared to matched controls. Tukey boxplot with 
whiskers indicating 1.5 interquartile range of the lower and upper 
quartile and black dot indicating an outlier.
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the NAD(P)H-oxidase subunits between patients and 
controls (Table 5). The range for each of these proteins 
was large in both groups, but the mean patient/control 
ratio for each of the quantified proteins in the individu-
ally matched pairs was close to 1 (Table 5).
Discussion
In this study, the aerobic exercise capacity of 17 patients 
in long-term remission from CS was compared to the 
aerobic exercise capacity of 17 healthy participants in-
dividually matched for sex, age, BMI, smoking behavior, 
ethnicity, and physical activity level. The rationale of 
matching for these variables was that they are major 
determinants of VO2peak. The main finding of this 
study is that the former CS patients have a significantly 
lower aerobic exercise capacity (VO2peak) than their in-
dividually matched controls. To investigate whether 
this lower VO2peak is the result of 1)  a reduced mito-
chondrial content, 2)  differences in the structure and 
density of the muscle capillary network, and/or 3)  an 
increased imbalance between the protein content and 
phosphorylation state of eNOS and of the subunits of 
the NAD(P)H-oxidase protein complex in the muscle 
microvasculature, muscle biopsies were collected to 
make these measurements in 7 or 8 patient/matched 
Table 2. Peak exercise responses and daily energy expenditure of patients and controls (n = 17)
Patients Controls P/C ratio P
VO2peak: (mL O2/kg/min) 28.0 ± 7.0 34.8 ± 7.9 0.80 <0.01
b
HR, bpm 174 ± 16 180 ± 13 0.97 0.22
Workload, watt 176 ± 49 212 ± 67 0.83 0.01a
VE, L/min 89.4 ± 27.3 101.0 ± 19.8 0.89 0.02
a
Respiratory rate, b/min 38 ± 8 42 ± 6 0.90 <0.05a
RER 1.22 ± 0.09 1.17 ± 0.08 1.04 0.11
Lactate, mmol/L 9.8 ± 2.8 11.0 ± 3.1 0.89 0.16
Test duration, min 12.0 ± 2.4 14.3 ± 3.8 0.84 0.02a
VO2/HR, mL/beat 12.0 ± 3.7 14.8 ± 4.2 0.83 0.01
a
Daily EE, cal 2498 ± 594 2567 ± 570 0.97 0.25
Daily active EE, cal 556 ± 527 606 ± 530 0.92 0.45
Daily sedentary h, < 1.5 METS) 10.7 ± 1.7 10.4 ± 1.6 1.03 0.54
Daily active h, > 3 METS) 4.1 ± 1.6 4.9 ± 1.8 0.84 0.12
Data are presented as mean ± SD.
Abbreviations: EE, energy expenditure; cal, calories; HR, heart rate; METS, metabolic equivalent of task scores; P/C ratio, mean of the ratio of the 
indicated variable measured in the patient and its matched control; RER, respiratory exchange ratio; VE, minute ventilation; VO2peak, maximal aerobic 
capacity.
aP less than .05.
bP less than .01.
Table 3. Peak exercise responses and daily energy expenditure of patients and controls after exclusion of 
couples containing a patient with treated hypothyroidism (n = 13)
Patients Controls P/C ratio P
VO2peak, mL O2/kg/min 25.2 ± 3.8 32.5 ± 5.5 0.78 < .01
b
HR, bpm 173 ± 18 178 ± 15 0.98 .43
Workload, watt 158 ± 33 192 ± 35 0.82 .01a
VE, L/min 80.8 ± 19.4 95.1 ± 15.9 0.85 .02
a
Respiratory rate, b/min 37 ± 8 42 ± 6 0.88 .06
RER 1.23 ± 0.08 1.17 ± 0.08 1.05 .10
Lactate, mmol/L 9.1 ± 2.6 10.3 ± 2.6 0.88 .24
Test duration, min 11.5 ± 2.2 14.0 ± 3.9 0.82 .03a
VO2/HR, mL/beat 10.6 ± 1.8 13.9 ± 3.4 0.76 < .01
b
Daily EE, cal 2288 ± 308 2374 ± 257 0.96 .24
Daily active EE, cal 408 ± 247 459 ± 250 0.89 .52
Daily sedentary h (< 1.5 METS) 11.1 ± 1.3 10.7 ± 1.4 1.04 .53
Daily active h (> 3 METS) 3.8 ± 1.4 4.6 ± 1.9 0.83 .17
Data are presented as mean ± SD.
Abbreviations: EE, energy expenditure; cal, calories; HR, heart rate; METS, metabolic equivalent of task scores; P/C ratio, mean of the ratio of the 
indicated variable measured in the patient and its matched control; RER, respiratory exchange ratio; VE, minute ventilation; VO2peak, maximal aerobic 
capacity.
aP less than .05.
bP less than .01.
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control pairs. Because the patient/matched control ratio 
for each of the measured variables was close to 1.0 
(Tables 4 and 5), this leads to the conclusion that the 
reduction in VO2peak in the patients must be the result of 
impairment in the blood supply to the exercising muscle 
or of a reduction in the efficiency of mitochondrial res-
piration (lower adenosine triphosphate/oxygen ratio) 
in the exercising muscle. This conclusion is important 
because it may explain the persistent complaints of fa-
tigue and lack of energy reported by this patient popu-
lation (1).
The lower aerobic exercise capacity in patients was 
independent of sex, age, BMI, and current physical ac-
tivity level because careful matching for these variables 
between individual patients and their control was per-
formed. The lower aerobic exercise capacity also did 
Table 4. Skeletal muscle capillarization and mitochondrial content
No. Patients Controls P/C ratio P
Mitochondrial content type 1 fibers 7 18.9 ± 4.3 19.4 ± 5.3 0.97 .89
Mitochondrial content type 2 fibers 7 13.8 ± 4.1 14.4 ± 4.2 0.96 .84
Capillary contacts type 1 fibers 8 4.3 ± 1.1 4.9 ± 1.5 0.88 .43
Capillary contacts type 2 fibers 8 3.3 ± 0.9 3.5 ± 1.0 0.94 .58
Average total fiber cross-sectional area, mm2 8 4527 ± 897 4846 ± 2364 0.93 .71
Average type 1 fiber cross-sectional area, mm2 8 5220 ± 1205 5251 ± 1836 0.99 .97
Average type 2 fiber cross-sectional area, mm2 8 3834 ± 1221 4439 ± 3033 0.86 .53
Average total fiber perimeter, mm2 8 320 ± 57 310 ± 90 1.03 .76
Average type 1 fiber perimeter, mm2 8 350 ± 84 322 ± 77 1.09 .48
Average type 2 fiber perimeter, mm2 8 290 ± 53 297 ± 108 0.97 .81
Total capillary-fiber perimeter exchange 8 4.9 ± 0.9 5.6 ± 1.1 0.88 .20
Type 1 capillary-fiber perimeter exchange 8 5.1 ± 1.3 6.4 ± 1.4 0.80 .14
Type 2 capillary-fiber perimeter exchange 8 4.6 ± 1.0 4.7 ± 1.0 0.98 .74
Capillary density, capillaries/mm2 8 569 ± 91 596 ± 93 0.95 .58
Mitochondrial content in type 1 and type 2 fibers was measured as the fluorescence intensity of COXIV. Data are presented as mean ± SD.
Abbreviations: COXIV, oxphos complex IV; P/C ratio, mean of the ratio of the indicated variable measured in the patient and its matched control.
Figure 2. Comparison of the eNOS and eNOS-P-ser1177 (eNOS phosphorylated on serine1177) content in skeletal muscle capillaries and arterioles 
in a former patient and the matched control. Cross-sectional images of muscle fibers were generated with a confocal immunofluorescence 
microscope. Capillaries and arterioles were visualized with Ulex europaeus-FITC–conjugated lectin (UEA-I in green; left panels), creating an 
endothelial mask for each individual microvessel. eNOS and PeNOS were visualized with specific primary and secondary antibodies on the same 
section so the eNOS/PeNOS fluorescence intensity ratio could be measured in each individual microvessel.
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not correlate with CS subtype, age at diagnosis, estrogen 
status, and duration of remission. Aerobic exercise cap-
acity in the CS patients and controls was inversely related 
to age in accordance with the existing literature (13). 
The patient group studied was not receiving any med-
ical treatment at the time of testing, except for thyroid 
hormone substitution in 4 patients. None of the patients 
had other hormonal deficiencies, nor other comorbidities, 
like hypertension or impaired glucose tolerance/diabetes. 
Therefore, the treatment outcome of these specific pa-
tients can be considered as a “best-case scenario,” and 
any observed difference in outcome is likely to be, at 
least in part, a persisting effect of preexposure to cor-
tisol excess, potentially affecting long-term outcome. 
Decreased aerobic exercise capacity has also been dem-
onstrated in untreated hypothyroidism. This is (at least 
partially) reversible when adequately treated (20). This 
effect may have negatively influenced VO2peak in the pa-
tient group. Indeed, in our patients with treated hypo-
thyroidism, VO2peak was lower than in patients without 
hypothyroidism. However, after excluding patients with 
treated hypothyroidism, VO2peak in patients in remis-
sion of CS remained significantly lower compared to the 
matched controls (Table 3).
One could argue that an explanation for our findings 
could be that patients in remission from CS are physic-
ally deconditioned during their previous episode of ac-
tive CS and/or have a more sedentary lifestyle. However, 
Figure 3. Comparison of the p47phox content (images in the middle) in skeletal muscle capillaries and arterioles (stained with UEA-I in images on 
the left) and in the plasma membrane of the skeletal muscle fibers (stained with WGA in images on the right) in a former patient and the matched 
control. The 3 stains were applied to a single cross-section for each individual. P47phox is present both in the endothelial mask of the capillaries and 
arterioles and mask of the plasma membrane of the skeletal muscle fibers (both in the former patient and the matched control).
Table 5. Skeletal muscle eNOS, eNOS ser1177, NOX2, p47phox, and p67phox protein content
No. Patients Controls P/C ratio P
eNOS protein content 8 86.0 ± 29.5 75.5 ± 21.7 1.14 .13
eNOS ser1177 phosphorylation 8 81.8 ± 14.5 75.9 ± 17.6 1.08 .16
eNOS ser1177/eNOS ratio 8 1.14 ± 0.4 1.20 ± 0.4 0.95 .59
Endothelial-specific NOX2 protein content 7 86.3 ± 28.5 88.0 ± 36.7 0.98 .72
Membrane-specific NOX2 protein content ratio 7 66.9 ± 22.1 70.6 ± 23.9 0.95 .22
p47phox 7 118.9 ± 38.3 120.7 ± 45.6 0.99 .95
p67phox 7 100.9 ± 24.3 112.3 ± 19.4 0.90 .23
The content of these proteins was measured as their fluorescence intensity as described in detail in “Methods.”
Abbreviations: eNOS, endothelial nitric oxide synthase; P/C ratio, mean of the ratio of the indicated variable measured in the patient and its matched 
control.
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individual patients were matched for physical activity 
levels with their controls and they had a similar daily 
EE, active EE, and the same amount of sedentary and 
active hours as their individual controls. This study does 
not provide information about the period shortly after 
surgery and therefore prospective studies are needed to 
determine whether a short-term physical rehabilitation 
program after surgery may improve long-term aerobic 
exercise capacity in these patients.
One could also argue that the interpretation of our 
data is influenced by the still-improving health status in 
the patients because the duration of remission is vari-
able. However, there are some facts arguing against this. 
In one of our previous publications, quality of life was 
investigated in patients in remission from CS for more 
than 2  years compared to matched controls (1). The 
study used the RAND-36 questionnaire, which includes 
questions regarding changes in general health status. The 
RAND-36 subdomain “health change” was the only do-
main that was not different between patients (in remis-
sion from CS for > 2 years) and controls. In addition, 
the patients in the present study have been in remission 
for more than 4 years and did not have comorbidities so 
it is unlikely that their health status is still improving. 
Furthermore, in active CS there is muscle atrophy with a 
diminished cross-sectional diameter of the muscle fibers 
(16). In the present study, the muscle fiber CSA of type 
I and type II fibers is exactly the same in patients and 
their individually matched controls independent of the 
length of time that the patients were in remission, and 
no significant correlation between duration of remission 
and VO2peak was found.
Several mechanisms could explain our finding of the 
lower aerobic exercise capacity (VO2peak) of the patients 
in long-term remission from CS. First, it could be the re-
sult of a reduced supply of arterial blood and therefore 
of oxygen-borne and blood-borne fuel to the skeletal 
muscle fibers during exercise. With regard to this explan-
ation, our group has previously shown that the vaso-
dilator response to acetylcholine, sodium nitroprusside, 
and NG-monomethyl-L-arginine compared to individu-
ally matched controls was normal using venous occlu-
sion plethysmography to measure total leg blood flow 
in patients with long-standing remission from CS (21). 
This implies that functioning of the larger conductance 
and resistance vessels in adequately treated patients in 
remission of CS is comparable to that of healthy con-
trols (21). However, this does not exclude that im-
paired exercise-induced vasodilation of the muscle 
TAs reduces the recruitment of additional capillaries 
and of additional capillary surface area available for 
transendothelial transport of oxygen and nutrients into 
the interstitium of the muscle for uptake and oxidation 
by the contracting muscle fibers (4).
This study did not show a statistically significant 
difference in the CSA of type I  and type II fibers, the 
mitochondrial content of type I and type II fibers, and 
all the capillary measures that were performed in the 
muscle biopsies of the patients and their individual con-
trols. There was also no difference in the ratio of the 
protein content of eNOS seen in the patients and their 
controls, and this also applies to the NOX2, p47phox 
and p67phox protein cluster. This implies that the protein 
balance between NO production by eNOS and scaven-
ging of NO by superoxide anions generated by NAD(P)
H-oxidase in the endothelial layer of TAs and capillaries 
is not different between the patients and their individu-
ally matched controls and that they, with 24-hour EE 
and number of physical activity hours being equal, are 
receiving the same training stimulus. The underlying 
assumption, that the protein expression of eNOS in-
creases with training load and that of the subunits of 
the NAD(P)H-oxidase protein complex decreases with 
training, is confirmed by previous observations of the au-
thors in exercise training studies in previously sedentary 
healthy lean men (19) and previously sedentary obese 
men with and without metabolic syndrome (6). Exercise 
training interventions inducing increases in VO2peak of 
10% to 20% led to significant 5% to 10% increases in 
eNOS protein content in both studies (6, 19), whereas 
the NOX2 protein content remained at the same low 
expression level in the healthy lean men (19) and was 
significantly reduced in the obese men by 10% (6). The 
absence in the present study of a significant difference in 
the protein content of eNOS and of the NOX2, p47phox, 
and p67phox protein cluster supports the assumption 
that the metabolic adaptation of the endothelial layer to 
an equal physical activity level and 24-hour EE was the 
same in the patients in remission from CS and their in-
dividually matched controls. We also matched patients 
and their controls for BMI because there is convincing 
evidence in the literature that the protein expression of 
p47phox (cytosolic activator of NAD(P)H-oxidase) in-
creases with BMI in vascular endothelial cells obtained 
from sedentary overweight and obese adults (22).
Although we did not find a lower mitochondrial 
COXIV content in type I  and type II muscle fibers in 
the patients compared to their controls (Table  4), we 
cannot exclude that the lower VO2peak is caused by a 
lower functional capacity (eg, the adenosine diphos-
phate/oxygen ratio) of the mitochondria in the patients. 
However, the finding of comparable lactate levels imme-
diately after exercise at VO2peak in the patients and their 
matched controls pleads against this option.
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A previous publication from our group provided evi-
dence that lower leg muscle mass was reduced in patients 
in long-term remission from CS in comparison to the 
general population (23). This theoretically could also ex-
plain the reduction in VO2peak that we observe in patients 
during incremental exercise. We can exclude that this is 
the case, however, in the present study because the pa-
tients and controls investigated in the present study were 
matched for the most important factors and conditions 
that affect VO2peak to include physical activity levels. The 
observation that the CSA of the type I and type II fibers 
did not differ between patients and their matched con-
trols also excludes a lower muscle mass in the patients. 
As explained by previous research (24), a lower muscle 
mass in sedentary compared to trained men and women 
(called disuse atrophy) always is the result of muscle fiber 
atrophy with by far the largest decrease in CSA occurring 
in type II fibers. Obesity and inflammation leading to 
skeletal muscle insulin resistance will enhance the se-
verity of disuse atrophy via larger increases in CSA.
In our study we focused on changes at the level of 
skeletal muscles that might cause reduced aerobic exer-
cise capacity. In addition, other factors such as cardiac 
output can also negatively affect aerobic exercise cap-
acity. A lower oxygen pulse was detected in the patients 
in long-term remission. This finding might be caused by 
a limitation in exercise cardiac output (25, 26). There 
is evidence that, despite long-term remission of CS, 
these patients have more coronary artery disease (27), 
subclinical biventricular and left atrium systolic dys-
function (28, 29) and increased left ventricular mass, 
diastolic dysfunction (29), and increased myocardial fi-
brosis (30). It is also known that these structural and 
functional abnormalities ameliorate already in the first 
year after remission, but do not fully disappear (28-31). 
These persistent abnormalities could in theory reduce 
cardiac contractility and cardiac output and therefore 
reduce the supply of oxygen to the active muscles.
As a limitation of this study, it should be mentioned 
that measurements of dehydroepiandrosterone sulfate 
(DHEA-S) were not included in this study because this 
measurement was not part of our routine clinical practice.
The data in this study might also have relevance 
for patients treated with exogenous glucocorticoids. 
Previous research has shown that acute glucocorticoid 
administration had a minimal effect on exercise cap-
acity and performance measures in healthy men, 
whereas short-term glucocorticoid administration of 5 
to 7  days improved performance (cycling time to ex-
haustion, maximal force while hopping, and knee ex-
tensor endurance time) (32). To our knowledge, there 
are no studies investigating the effects of long-term 
glucocorticoid use (of similar duration as the exposure 
to excess glucocorticoids experienced by CS patients be-
fore surgery) on exercise capacity in healthy individuals.
In conclusion, this is the first study that demon-
strates that patients in long-term remission from CS 
have a lower aerobic exercise capacity when com-
pared to a well-matched, healthy control group. In 
addition, this study demonstrates that this finding is 
independent of current daily activity levels. The study 
is the first to generate evidence that there are no dif-
ferences between patients and matched controls in the 
cross-sectional area of muscle fiber types, any of the 
capillary measures, and mitochondrial content. There 
were also no significant differences in the ratio of the 
protein content of eNOS and producing NO and of the 
subunits of NAD(P)H-oxidase–producing superoxide 
anions. These findings need validation in a prospective 
study with a larger cohort of patients making multiple 
measurements over a 6- to 7-year period. The finding 
of a decreased oxygen pulse in patients during exer-
cise testing warrants further investigation into cardiac 
function in this future prospective study. Although CS 
is a rare disorder, glucocorticoids are frequently used 
as therapeutic agents in a wide spectrum of diseases. 
Therefore, our observations are relevant for medicine 
in general.
Acknowledgments
We thank Lisanne Janssen for her assistance during the per-
formance of the exercise tests and Yvonne Hartman for ana-
lyzing the number of sedentary hours in the Sensewear data.
Financial Support: This work was supported by the Dutch 
Adrenal Society NVACP and the Dutch Adrenal Fund.
Clinical Trial Registration Number: CMO 2012-188.
Additional Information
Correspondence: Sean H. P. P. Roerink, MD, Department of 
Endocrinology (471), PO Box 9101, 6500 HB Nijmegen, the 
Netherlands. E-mail: sean.roerink@radboudumc.nl.
Disclosure Summary: The authors have nothing to dis-
close.
References
 1. Wagenmakers  MA, Netea-Maier  RT, Prins  JB, Dekkers  T, 
den Heijer M, Hermus AR. Impaired quality of life in patients 
in long-term remission of Cushing’s syndrome of both ad-
renal and pituitary origin: a remaining effect of long-standing 
hypercortisolism? Eur J Endocrinol. 2012;167(5):687–695.
 2. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in 
patients after long-term biochemical cure of Cushing’s disease. J 
Clin Endocrinol Metab. 2005;90(6):3279–3286.
 3. Pikkarainen L, Sane T, Reunanen A. The survival and well-being 
of patients treated for Cushing’s syndrome. J Intern Med. 
1999;245(5):463–468.
10  Roerink et al  Mechanisms Limiting Aerobic Exercise Capacity After Cushing Syndrome J Clin Endocrinol Metab, April 2020, 105(4):1–11
Copyedited by: Oup
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/4/dgz286/5681573 by guest on 17 M
arch 2020
 4. Wagenmakers AJ, Strauss JA, Shepherd SO, Keske MA, Cocks M. 
Increased muscle blood supply and transendothelial nutrient and 
insulin transport induced by food intake and exercise: effect of 
obesity and ageing. J Physiol. 2016;594(8):2207–2222.
 5. Keske MA, Premilovac D, Bradley EA, Dwyer RM, Richards SM, 
Rattigan S. Muscle microvascular blood flow responses in insulin 
resistance and ageing. J Physiol. 2016;594(8):2223–2231.
 6. Cocks  M, Shaw  CS, Shepherd  SO, et  al. Sprint interval and 
moderate-intensity continuous training have equal benefits on 
aerobic capacity, insulin sensitivity, muscle capillarisation and 
endothelial eNOS/NAD(P)H oxidase protein ratio in obese men. 
J Physiol. 2016;594(8):2307–2321.
 7. Nieman  LK, Biller  BM, Findling  JW, et  al. The diagnosis of 
Cushing’s syndrome: an Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540.
 8. Mossberg KA, Masel BE, Gilkison CR, Urban RJ. Aerobic cap-
acity and growth hormone deficiency after traumatic brain injury. 
J Clin Endocrinol Metab. 2008;93(7):2581–2587.
 9. Molitch  ME, Clemmons  DR, Malozowski  S, et  al; Endocrine 
Society’s Clinical Guidelines Subcommittee. Evaluation and 
treatment of adult growth hormone deficiency: an Endocrine 
Society Clinical Practice Guideline. J Clin Endocrinol Metab. 
2006;91(5):1621–1634.
 10. Ainsworth  BE, Haskell  WL, Herrmann  SD, et  al. 2011 
Compendium of Physical Activities: a second update of codes and 
MET values. Med Sci Sports Exerc. 2011;43(8):1575–1581.
 11. Oliveira RB, Myers J, Araújo CG, Abella J, Mandic S, Froelicher V. 
Maximal exercise oxygen pulse as a predictor of mortality among 
male veterans referred for exercise testing. Eur J Cardiovasc Prev 
Rehabil. 2009;16(3):358–364.
 12. Borg  G. Perceived exertion as an indicator of somatic stress. 
Scand J Rehabil Med. 1970;2(2):92–98.
 13. Balady  GJ, Arena  R, Sietsema  K, et  al; American Heart 
Association Exercise, Cardiac Rehabilitation, and Prevention 
Committee of the Council on Clinical Cardiology; Council on 
Epidemiology and Prevention; Council on Peripheral Vascular 
Disease; Interdisciplinary Council on Quality of Care and 
Outcomes Research. Clinician’s guide to cardiopulmonary exer-
cise testing in adults: a scientific statement from the American 
Heart Association. Circulation. 2010;122(2):191–225.
 14. Fruin  ML, Rankin  JW. Validity of a multi-sensor armband in 
estimating rest and exercise energy expenditure. Med Sci Sports 
Exerc. 2004;36(6):1063–1069.
 15. Tarnopolsky MA, Pearce E, Smith K, Lach B. Suction-modified 
Bergström muscle biopsy technique: experience with 13,500 pro-
cedures. Muscle Nerve. 2011;43(5):717–725.
 16. Rebuffé-Scrive M, Krotkiewski M, Elfverson J, Björntorp P. Muscle 
and adipose tissue morphology and metabolism in Cushing’s 
syndrome. J Clin Endocrinol Metab. 1988;67(6):1122–1128.
 17. Shepherd  SO, Cocks  M, Tipton  KD, et  al. Sprint interval and 
traditional endurance training increase net intramuscular trigly-
ceride breakdown and expression of perilipin 2 and 5. J Physiol. 
2013;591(3):657–675.
 18. Cocks  M, Shepherd  SO, Shaw  CS, Achten  J, Costa  ML, 
Wagenmakers  AJ. Immunofluorescence microscopy to assess 
enzymes controlling nitric oxide availability and microvascular 
blood flow in muscle. Microcirculation. 2012;19(7):642–651.
 19. Cocks M, Shaw CS, Shepherd SO, et al. Sprint interval and en-
durance training are equally effective in increasing muscle micro-
vascular density and eNOS content in sedentary males. J Physiol. 
2013;591(3):641–656.
 20. Caraccio N, Natali A, Sironi A, et al. Muscle metabolism and exer-
cise tolerance in subclinical hypothyroidism: a controlled trial of 
levothyroxine. J Clin Endocrinol Metab. 2005;90(7):4057–4062.
 21. Wagenmakers  MA, Roerink  SH, Schreuder  TH, et  al. Vascular 
health in patients in remission of Cushing’s syndrome is com-
parable with that in BMI-matched controls. J Clin Endocrinol 
Metab. 2016;101(11):4142–4150.
 22. Silver AE, Beske SD, Christou DD, et al. Overweight and obese 
humans demonstrate increased vascular endothelial NAD(P)H 
oxidase-p47(phox) expression and evidence of endothelial oxida-
tive stress. Circulation. 2007;115(5):627–637.
 23. Wagenmakers M, Roerink S, Gil L, et al. Persistent centripetal fat 
distribution and metabolic abnormalities in patients in long-term 
remission of Cushing’s syndrome. Clin Endocrinol (Oxf). 
2015;82(2):180–187.
 24. Saltin B, Henriksson J, Nygaard E, Andersen P, Jansson E. Fiber 
types and metabolic potentials of skeletal muscles in sedentary 
man and endurance runners. Ann N Y Acad Sci. 1977;301:3–29.
 25. Munhoz EC, Hollanda R, Vargas JP, et al. Flattening of oxygen 
pulse during exercise may detect extensive myocardial ischemia. 
Med Sci Sports Exerc. 2007;39(8):1221–1226.
 26. American Thoracic Society, American College of Chest Physicians. 
ATS/ACCP statement on cardiopulmonary exercise testing. Am J 
Respir Crit Care Med. 2003;167(2):211–277.
 27. Barahona MJ, Resmini E, Viladés D, et al. Coronary artery disease 
detected by multislice computed tomography in patients after 
long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab. 
2013;98(3):1093–1099.
 28. Kamenický P, Redheuil A, Roux C, et al. Cardiac structure and 
function in Cushing’s syndrome: a cardiac magnetic resonance im-
aging study. J Clin Endocrinol Metab. 2014;99(11):E2144–E2153.
 29. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. 
Cardiac dysfunction is reversed upon successful treatment of 
Cushing’s syndrome. Eur J Endocrinol. 2010;162(2):331–340.
 30. Yiu KH, Marsan NA, Delgado V, et al. Increased myocardial fi-
brosis and left ventricular dysfunction in Cushing’s syndrome. 
Eur J Endocrinol. 2012;166(1):27–34.
 31. Toja  PM, Branzi  G, Ciambellotti  F, et  al. Clinical relevance of 
cardiac structure and function abnormalities in patients with 
Cushing’s syndrome before and after cure. Clin Endocrinol 
(Oxf). 2012;76(3):332–338.
 32. Tacey A, Parker L, Garnham A, Brennan-Speranza TC, Levinger I. 
The effect of acute and short term glucocorticoid adminis-
tration on exercise capacity and metabolism. J Sci Med Sport. 
2017;20(6):543–548.
doi:10.1210/clinem/dgz286 https://academic.oup.com/jcem  11
Copyedited by: Oup
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/4/dgz286/5681573 by guest on 17 M
arch 2020
